HomeCompareSSPGX vs ABBV

SSPGX vs ABBV: Dividend Comparison 2026

SSPGX yields 384.62% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SSPGX wins by $8595.82M in total portfolio value
10 years
SSPGX
SSPGX
● Live price
384.62%
Share price
$0.52
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8595.92M
Annual income
$5,687,167,359.75
Full SSPGX calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SSPGX vs ABBV

📍 SSPGX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSSPGXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SSPGX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SSPGX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SSPGX
Annual income on $10K today (after 15% tax)
$32,692.31/yr
After 10yr DRIP, annual income (after tax)
$4,834,092,255.79/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SSPGX beats the other by $4,834,071,199.78/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SSPGX + ABBV for your $10,000?

SSPGX: 50%ABBV: 50%
100% ABBV50/50100% SSPGX
Portfolio after 10yr
$4298.01M
Annual income
$2,843,596,065.76/yr
Blended yield
66.16%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SSPGX
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SSPGX buys
0
ABBV buys
0
No recent congressional trades found for SSPGX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSSPGXABBV
Forward yield384.62%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$8595.92M$102.3K
Annual income after 10y$5,687,167,359.75$24,771.77
Total dividends collected$8325.35M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SSPGX vs ABBV ($10,000, DRIP)

YearSSPGX PortfolioSSPGX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$49,162$38,461.54$11,550$430.00+$37.6KSSPGX
2$229,316$176,712.93$13,472$627.96+$215.8KSSPGX
3$1,015,727$770,358.78$15,906$926.08+$999.8KSSPGX
4$4,275,810$3,188,982.79$19,071$1,382.55+$4.26MSSPGX
5$17,121,253$12,546,135.48$23,302$2,095.81+$17.10MSSPGX
6$65,270,573$46,950,832.41$29,150$3,237.93+$65.24MSSPGX
7$237,118,507$167,278,994.25$37,536$5,121.41+$237.08MSSPGX
8$821,660,991$567,944,188.45$50,079$8,338.38+$821.61MSSPGX
9$2,718,462,559$1,839,285,298.29$69,753$14,065.80+$2718.39MSSPGX
10$8,595,922,297$5,687,167,359.75$102,337$24,771.77+$8595.82MSSPGX

SSPGX vs ABBV: Complete Analysis 2026

SSPGXStock

The fund invests at least 80% of its net assets in equity securities, such as common and preferred stocks. It invests primarily in a limited number of large and medium sized companies (meaning companies with market capitalizations of $2 billion or more) that the fund's investment adviser, believes have above-average growth histories and/or growth potential. The fund also may invest up to 25% of its total assets in foreign securities and up to 20% of its net assets (plus any borrowings for investment purposes) in debt securities. It is non-diversified.

Full SSPGX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SSPGX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SSPGX vs SCHDSSPGX vs JEPISSPGX vs OSSPGX vs KOSSPGX vs MAINSSPGX vs JNJSSPGX vs MRKSSPGX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.